[{"id":"315f3515-a4e3-4f7b-9cbb-e4e107970247","acronym":"","url":"https://clinicaltrials.gov/study/NCT06186076","created_at":"2023-12-29T19:18:43.407Z","updated_at":"2024-07-02T16:35:24.886Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients","source_id_and_acronym":"NCT06186076","lead_sponsor":"Therapex Co., Ltd","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TRX-221"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-12-29"}]